| Date Filed | Type | Description |
| 08/23/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 05/26/2023 |
SC 13D/A
| AGENUS INC reports a 62.5% stake in MINK THERAPEUTICS, INC. |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/24/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/14/2023 |
8-K
| Quarterly results|
Docs:
|
"Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer , 50% in PD-1 refractory non-small cell lung cancer and in seven additional metastatic, late-line cancers in a total of more than 300 patients Randomized Phase 2 trials in MSS CRC, melanoma, and pancreatic cancers are underway; a confirmatory phase 3 trial in MSS CRC is expected to be launched in 2023 Data demonstrating clinical benefit in MSS CRC, NSCLC, ovarian cancer, and sarcomas were presented in plenary sessions at ESMO GI, SITC, and CTOS in 2022, and in a late-breaking oral session at ASCO GI in January 2023 Existing corporate collaborations have potential to generate up to $2.7B ..." |
|
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 8% stake in Agenus Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/23/2022 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 12/02/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/11/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/05/2022 |
8-K
| Quarterly results |
| 06/22/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/14/2022 |
8-K
| Quarterly results |
| 06/09/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/08/2022 |
SC 13G
| Deep Track Capital, LP reports a 5.9% stake in Agenus Inc. |
| 03/25/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|